# Thrafford

> Lifescience


## Pages

- [dummy 06 nov](https://thrafford.com/dummy-06-nov/): At Thrafford, we’re pioneering the next generation of cell therapy manufacturing — making treatments more affordable, scalable, and accessible to patients everywhere. Our breakthrough technologies are designed to overcome the biggest challenges in the cell therapy industry: cost, complexity, and limited reach. Our Three-Pillar Approach Affordability Shifting from Autologous to Allogeneic Therapies: Today’s autologous (patient-specific) CAR-T therapies are expensive and time-intensive. Thrafford is transforming this model with healthy donor–derived allogeneic cells — one production batch serving multiple patients. This shift dramatically lowers the cost per treatment, paving the way for truly accessible advanced therapies. One batch manufacturing. Multiple patients. Lower […]
- [Technology](https://thrafford.com/technology/): ✅ PoCMAP ✅ Allogeneic ✅ Autologous ✅ PoCMAP ✅ Allogeneic ✅ Autologous ✅ PoCMAP ✅ Allogeneic ✅ Autologous ❮ ❯ At Thrafford, we’re pioneering the next generation of cell therapy manufacturing — making treatments more affordable, scalable, and accessible worldwide. Our Three-Pillar Approach Affordability Allogeneic donor-derived cell therapy significantly lowers costs by enabling multi-patient manufacturing from a single batch. One batch — many patients. Lower cost. Scalability A modular cell manufacturing platform delivering up to 40× capacity through parallel multi-batch processing. Parallel. Modular. 40× capacity. Accessibility India’s first point-of-care CAR-T manufacturing model, enabling therapy production directly inside hospital environments. Faster […]
- [Anita Chugh](https://thrafford.com/anita-chugh/): Dr. Anita Chugh Co-Founder & CSO, Thrafford Lifescience Organizational Growth & Program Leadership: At Ranbaxy, Advinus, and Syngene, I played a central role in establishing and scaling innovations into globally recognized products, platforms and services. These responsibilities demanded not only scientific vision but also the design of programs, systems, and policies that delivered sustainable growth. At Syngene, I led a division of over 180 scientists, achieving nearly five-fold growth in revenues while embedding performance metrics and global best practices. Advancing Research & Translational Impact: I have led and contributed to the advancement of 50+ therapeutic candidates from bench to clinic, […]
- [Kadalmani Krishnan](https://thrafford.com/kadalmani-krishnan/): Dr. Kadalmani Krishnan Founder & CEO 🎓 Post Doctoral Fellow, Harvard University, USA 🎓 Ph.D., University of Cambridge, UK 🎓 M.Sc., Bangalore University, India 📘 NIDA Clinical Trials Network – GCP, NIH (USA) ✅ Certified Lean Six Sigma Green Belt, Exemplar Global Key Areas Translational Immuno-Biology Metabolic Disorders and Therapeutics Clinical Efficacy & Safety Evaluation Biomanufacturing & Precision Therapeutics Point-of-Care Cell Therapy Manufacturing (PoCMAP) AI & Quantum-driven Biomedical Research Research & Media Highlights Talks YouTube – TEDx lecture Skill Development Programme Expert Insights – Cell & Gene Therapy Clinical Research Excellence – Navitas Papers Developed & Launched GLP-1 RA Biosimilar […]
- [dummy 1](https://thrafford.com/dummy-1/): Dr. Kadalmani Krishnan Founder, Thrafford Lifescience Dr. Kadalmani Krishnan is the Founder of Thrafford Lifescience, where he integrates science, strategy, and innovation to drive transformative healthcare solutions. He has led the development of an IP-driven point-of-care biomanufacturing platform, secured multi-source funding, and built global collaborations with leading institutions including AIIMS, THSTI, ICMR, MITVP, IBM, and others. Previously, as General Manager – Strategy & Drug Development at Levim Lifetech, Dr. Krishnan spearheaded the creation of India’s first GLP-1 receptor agonist biosimilar, achieving near-total import substitution in diabetes care and earning the DBT Innovator Award. His strategic leadership has advanced multiple therapeutic […]
- [Chapters in Books](https://thrafford.com/chapters-in-books/): Chapters in Books Gupta, Y.K., & Chugh, A. (2003). Digitalis and newer positive inotropic agents. In S.D. Seth, S.K. Manchanda, & S. Seth (Eds.), Recent advances in cardiovascular therapy of cardiovascular diseases (pp. [page numbers]). Jaypee Brothers Medical Publishers. Endothelin receptors: Targets for drug development. Ray, Abhijit; Hegde, Laxminarayan G.; Chugh, Anita; Gupta, Jang B. Edited By: Gupta, S. K. Pharmacology and Therapeutics in the New Millennium, [International Congress on Frontiers in Pharmacology and Therapeutics in 21st Century], New Delhi, India, Dec., 1999 (2001), 18-24.
- [Awards & fellowships](https://thrafford.com/awards-fellowships/): Awards & fellowships Dr. Kadalmani Krishnan Innovator Award in the area of Healthcare, Dept. of Biotechnology, India…………………….. [2023] NMB, BIRAC, DBT, India, grant….…………….……………………………………………………………………… [2023 – ongoing] Cambridge Commonwealth Trust (CCT) Award, Cambridge, UK…………………..………………… [2006 – 2010] National Overseas Doctoral Award, Govt. of India…………………………………………….…………… [2006 – 2010] Philosophical Society Award, Cambridge, UK…………………..………………………………………………[2007] Sanger, Perham and Darwin College Travel Award, Cambridge, UK…………………………….……[2006 – 2008] AU-KBC Research Foundation fellowship, Chennai, India……………..………………………………….[2001 – 2004] Biotech Consortium India Limited (BCIL) fellowship, New Delhi, India…..…………………………[2000 – 2001]     Dr. Anita Chugh Ranbaxy Excellence Award, India………………………………………………………………………………………[2008] Research Associate Fellowship, AIIMS, India………………………………………………………………..……[1992-1993] AIIMS Institute Fellowship by DGHS……………………………….………………………………………………..[1986-1989]
- [Published Patents](https://thrafford.com/published-patents/): Patent List Patent & Publication List Preparation of heterocyclic compounds as adrenergic receptor antagonists Sarma, Pakala Kumara Savithru; Kondaskar, Atul; et al. 2010, IN 2005DE03142 A 20100305 Preparation of 3,6-disubstituted azabicyclo[3.1.0]hexane derivatives useful as therapeutic muscarinic receptor antagonists Salman, Mohammad; Kumar, Naresh; et al. (2009), IN 2005DN01810 A 20091009 A process for the synthesis of 1,4-disubstituted piperazine derivatives Anand, Nitya; Jain, Sanjay; et al. (2009), IN 2005DE02911 A 20090731
- [Granted Patents](https://thrafford.com/granted-patents/): Granted Patents Selected Patents 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application By Mookhtiar, Kasim A.; Bhuniya, Debnath; Dave, Bhavesh; Kapkoti, Gobind S.; Basu, Sujay; Chugh, Anita; De, Siddhartha; Palle, Venkata P. Patent Number: 8940900   |   Type: Grant Filed: February 25, 2008   |   Date of Patent: January 27, 2015 Assignee: Advinus Therapeutics Private Limited Substituted pyrrole derivatives and their use as HMG-CO inhibitors By Salman, Mohammad; Sattigeri, Jitendra; Kumar, Yatendra; Aryan, Ram Chander; Ramanathan, Vikram Krishna; Chugh, Anita Patent Number: 7923467   |   Type: Grant Filed: May 28, 2004   |   […]
- [Publications](https://thrafford.com/publications/): Publications Kadalmani Krishnan, Anita Chugh, et al. Computational modeling and optimization of CAR-T cell receptors targeting CD19 for enhanced efficacy and minimized toxicity. Preprint at Research Square. DOI:10.21203/rs.3.rs-6115435/v2, 2025 Krishnan, K., Chugh, A., Niranjan, V., & Dhar, P. K. Recoding Genomic Elements with AI and Quantum Computation to Build the Next Generation Drug Discovery Platform. Preprints, 2025 Kadalmani Krishnan, Srikar Raman, et al. Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 Diabetes. Diabetes Research and Clinical Practice, 2023 Bansode, S.; Singh, P. K.; Tellis, M.; Chugh, A.; […]
- [Contact](https://thrafford.com/contact/): Get in Touch Thrafford Lifescience Pvt. Ltd. BSC BioNEST Bio-Incubator (BBB)Regional Centre for Biotechnology3rd Milestone, Faridabad–Gurugram ExpresswayFaridabad – 121001, Haryana, INDIA 📞 +91 84479 89735✉️ contact@thrafford.com
- [Team](https://thrafford.com/team/):               Dr. Kadalmani Krishnan                Founder & CEO               Ph.D., University of Cambridge, UK              Post-doctoral Fellow, Harvard University, USA              Biochemist with 20+ years of experience in product               development, GMP manufacturing, Pre-clinical and                 clinical trials.                            Dr. Anita Chugh               Co-Founder […]
- [Home](https://thrafford.com/): ✅ Advanced CAR-T Therapy ✅ Innovations in Cell & Gene Therapy ✅ Hope for Cancer Patients in India ✅ Advanced CAR-T Therapy ✅ Innovations in Cell & Gene Therapy ✅ Hope for Cancer Patients in India ✅ Advanced CAR-T Therapy ✅ Innovations in Cell & Gene Therapy ✅ Hope for Cancer Patients in India ❮ ❯ In countries like India, cancer patients face huge challenges in accessing the advanced affordable therapies like cell & gene therapy. For instance, there are about 250,000 Lymphoma & Leukemia cases in India and about 30% of these cases are relapsed & refractory—meaning that these […]


[comment]: # (Generated by Hostinger Tools Plugin)